company background image
TRU

TruScreen GroupNZSE:TRU Stock Report

Last Price

NZ$0.085

Market Cap

NZ$30.8m

7D

-3.4%

1Y

-43.0%

Updated

22 Jan, 2022

Data

Company Financials
TRU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

TRU Stock Overview

Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for TruScreen Group
Historical stock prices
Current Share PriceNZ$0.085
52 Week HighNZ$0.15
52 Week LowNZ$0.055
Beta0.56
1 Month Change6.25%
3 Month Change-3.41%
1 Year Change-42.95%
3 Year Change-54.05%
5 Year Change-46.88%
Change since IPO-39.29%

Recent News & Updates

Oct 20
Here's Why We're Not Too Worried About TruScreen Group's (NZSE:TRU) Cash Burn Situation

Here's Why We're Not Too Worried About TruScreen Group's (NZSE:TRU) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Jun 07
We Think TruScreen Group (NZSE:TRU) Can Afford To Drive Business Growth

We Think TruScreen Group (NZSE:TRU) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

TRUNZ Medical EquipmentNZ Market
7D-3.4%-5.3%-3.1%
1Y-43.0%-14.3%-11.4%

Return vs Industry: TRU underperformed the NZ Medical Equipment industry which returned -14.3% over the past year.

Return vs Market: TRU underperformed the NZ Market which returned -11.4% over the past year.

Price Volatility

Is TRU's price volatile compared to industry and market?
TRU volatility
TRU Average Weekly Movement5.8%
Medical Equipment Industry Average Movement8.3%
Market Average Movement3.8%
10% most volatile stocks in NZ Market6.5%
10% least volatile stocks in NZ Market2.4%

Stable Share Price: TRU is more volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: TRU's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of NZ stocks.

About the Company

FoundedEmployeesCEOWebsite
2013n/aJuliet Hullhttps://truscreen.com

Truscreen Group Limited, together with its subsidiaries, develops, manufactures, and sells cancer detection devices and systems in Mexico, China, Russia, Vietnam, Zimbabwe, and internationally. The company offers the TruScreen cervical cancer screening system, a medical device for detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to Truscreen Group Limited in August 2020.

TruScreen Group Fundamentals Summary

How do TruScreen Group's earnings and revenue compare to its market cap?
TRU fundamental statistics
Market CapNZ$30.84m
Earnings (TTM)-NZ$3.24m
Revenue (TTM)NZ$2.24m

13.8x

P/S Ratio

-9.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TRU income statement (TTM)
RevenueNZ$2.24m
Cost of RevenueNZ$900.71k
Gross ProfitNZ$1.34m
ExpensesNZ$4.58m
Earnings-NZ$3.24m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0089
Gross Margin59.76%
Net Profit Margin-144.70%
Debt/Equity Ratio0.0%

How did TRU perform over the long term?

See historical performance and comparison

Valuation

Is TruScreen Group undervalued compared to its fair value and its price relative to the market?

3.2x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TRU's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TRU is unprofitable, so we can't compare its PE Ratio to the Oceanic Medical Equipment industry average.

PE vs Market: TRU is unprofitable, so we can't compare its PE Ratio to the NZ market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRU's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRU is good value based on its PB Ratio (3.2x) compared to the XO Medical Equipment industry average (4.2x).


Future Growth

How is TruScreen Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TruScreen Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has TruScreen Group performed over the past 5 years?

-5.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRU is currently unprofitable.

Growing Profit Margin: TRU is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRU is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare TRU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRU is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (57.5%).


Return on Equity

High ROE: TRU has a negative Return on Equity (-33.54%), as it is currently unprofitable.


Financial Health

How is TruScreen Group's financial position?


Financial Position Analysis

Short Term Liabilities: TRU's short term assets (NZ$5.5M) exceed its short term liabilities (NZ$649.0K).

Long Term Liabilities: TRU's short term assets (NZ$5.5M) exceed its long term liabilities (NZ$36.2K).


Debt to Equity History and Analysis

Debt Level: TRU is debt free.

Reducing Debt: TRU had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRU has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TRU has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 4.8% each year.


Dividend

What is TruScreen Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRU's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Juliet Hull

0.83

Tenure

NZ$36,904

Compensation

Ms. Juliet Hull B. Nurse ATI, MBA MGS, serves as Interim Chief Executive Officer at TruScreen Group Limited since March 2021 and serves as its Executive Director since September 10, 2020 and served as its...


CEO Compensation Analysis

Compensation vs Market: Juliet's total compensation ($USD24.83K) is below average for companies of similar size in the NZ market ($USD370.35K).

Compensation vs Earnings: Insufficient data to compare Juliet's compensation with company performance.


Leadership Team

Experienced Management: TRU's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: TRU's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

TruScreen Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: TruScreen Group Limited
  • Ticker: TRU
  • Exchange: NZSE
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: NZ$30.844m
  • Shares outstanding: 362.87m
  • Website: https://truscreen.com

Location

  • TruScreen Group Limited
  • Equitable House
  • Level 6
  • Auckland
  • 1010
  • New Zealand

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/22 06:01
End of Day Share Price2022/01/21 00:00
Earnings2021/09/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.